ARVs to Prevent Breastmilk HIV:Viral and Immune Responses

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 3, 2003

Primary Completion Date

March 31, 2005

Study Completion Date

April 30, 2006

Conditions
HIV Infections
Interventions
DRUG

Combined short-course zidovudine/nevirapine

300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight \> 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.

DRUG

HAART

300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.

Trial Locations (1)

Unknown

University of Nairobi, Nairobi

All Listed Sponsors
collaborator

Elizabeth Glaser Pediatric AIDS Foundation

OTHER

lead

University of Washington

OTHER

NCT00167674 - ARVs to Prevent Breastmilk HIV:Viral and Immune Responses | Biotech Hunter | Biotech Hunter